Maraviroc reduces viral load in naive patients at ...[AIDS Patient Care STDS. 2007]

SearchDatabase nameforSearch term

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Maraviroc reduces viral load in naive patients at 48 weeks.

[No authors listed]

PMID: 17941136 [PubMed - indexed for MEDLINE]

Maraviroc--new HIV drug. Emerging options need to be used wisely.
Posit Aware. 2007 Jul-Aug; 18(4):18-9.

[Posit Aware. 2007]
Anti-HIV agents. Using maraviroc in first-line therapy.
TreatmentUpdate. 2007 Sep-Oct; 19(6):5-6.

[TreatmentUpdate. 2007]
ReviewMaraviroc.
Drugs. 2007; 67(15):2277-88; discussion 2289-90.

[Drugs. 2007]
[Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances]
MMW Fortschr Med. 2008 Apr 28; 150 Spec No 1:52-3.

[MMW Fortschr Med. 2008]
Review[Maraviroc efficacy in clinical studies on the development of the molecule]
Enferm Infecc Microbiol Clin. 2008 Oct; 26 Suppl 11:17-22.

[Enferm Infecc Microbiol Clin. 2008]
» See reviews... | » See all...

Efavirenz (Sustiva® , Atripla® (as a combination product containing Efavirenz, Emtricitabine, and Tenofovir))
Efavirenz is used with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Efavirenz is in a class of medications called nonnucle...
Maraviroc (Selzentry® )
Maraviroc is used with other medications to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Maraviroc is in a class of antiviral medications called CCR5 co-...
Source: AHFS Consumer Medication Information

Your browsing activity is empty.

Activity recording is turned off.

Display Show